$SBFM News

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering

Sunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution Concerns

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

Sunshine Biopharma Amends Articles Of Incorporation To Allow For Reverse Stock Split Of Up To 1-For-20; Board Of Directors Has Discretion To Effect The Split

Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know

Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio

Sunshine Biopharma Launches Generic Ondansetron Tablets Of 4mg And 8mg In Canadian Market

Sunshine Biopharma Says CEO Steve Slilaty, Holder Of About 97% Of Voting Power, Approved Reverse Stock Split Of Up To 1-For-20 By Written Consent

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

Sunshine Biopharma Announces Approval Of Atenolol Tablets Of 25mg, 50mg And 100mg For Canadian Market

EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer

Sunshine Biopharma Announces Updates On Its K1.1 mRNA Tumor Suppressor; Outlines Plans For Program

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug

Sunshine Biopharma Announces Approval Of Generic Enalapril Tablets 2.5mg, 5mg, 10mg And 20mg For Canadian Market

EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market